中国中医药信息杂志2025，Vol.32Issue(4)：152-156,5.DOI:10.19879/j.cnki.1005-5304.202408330
肾衰Ⅱ号颗粒治疗慢性肾脏病3～4期脾肾气虚、湿热瘀阻证患者临床疗效及对游离脂肪酸水平的影响
Clinical Efficacy of Shenshuai Ⅱ Granules in the Treatment of Chronic Kidney Disease Stage 3-4 with Spleen-Kidney Qi Deficiency and Damp-Heat Stasis Syndrome and Its Effects on Free Fatty Acid
摘要
Abstract
Objective To observe the clinical efficacy of Shenshuai Ⅱ Granules on patients with stage 3-4 chronic kidney disease(CKD)with spleen-kidney qi deficiency and damp-heat stasis syndrome and its effects on free fatty acid(FFA)levels.Methods A randomized double-blind clinical trial design was adopted,and 84 cases were included and randomly divided into a control group and a treatment group,with 42 cases in each group.The control group was given placebo granules,and the treatment group was given Shenshuai Ⅱ Granules,once a bag,twice a day,orally taken with warm water;the treatment for both groups lasted 3 months.Clinical efficacy and TCM syndrome efficacy of the two groups were evaluated.Renal function indicators(SCr,BUN,eGFR,24 hUP)and lipid metabolism indicators(FFA,TC,TG,LDL-C,HDL-C,LP(a),ApoA1 and ApoB)were detected and compared before and after treatment.The safety indicators of both groups were monitored.Results The total clinical effective rate of the treatment group was 83.33%(35/42),and the rate of the control group was 35.71%(13/42),with statistical significance(P<0.01);the therapeutic effect of TCM syndrome efficacy of the treatment group was 88.10%(37/42),and the rate of the control group was 40.48%(17/42),with statistical significance(P<0.01).Compared with before treatment,the levels of SCr,BUN,24-hour UP,FFA decreased in the treatment group,and eGFR increased(P<0.05,P<0.01).After treatment in the control group,SCr increased,while eGFR decreased(P<0.01).After treatment,the SCr,BUN and FFA levels in the treatment group were lower than those in the control group(P<0.01).There was no statistical significance in TC,TG,LDL-C,HDL-C,Lp(a),ApoA1 and ApoB between the two groups before and after treatment(P>0.05).No abnormal changes were observed in the safety indicators of the two groups of patients(P>0.05).Conclusion Shenshuai Ⅱ Granules integrated treatment with Western medicine can improve clinical symptoms and renal function-related indicators on patients with stage 3-4 CKD with spleen-kidney qi deficiency and damp-heat stasis syndrome,reduce serum FFA,and delay the progression of CKD.关键词
慢性肾脏病/肾衰Ⅱ号颗粒/脂代谢/血清游离脂肪酸Key words
chronic kidney disease/Shenshuai Ⅱ Granules/lipid metabolism/serum free fatty acids分类
医药卫生引用本文复制引用
丁晓璐,蔡峥,王琛..肾衰Ⅱ号颗粒治疗慢性肾脏病3～4期脾肾气虚、湿热瘀阻证患者临床疗效及对游离脂肪酸水平的影响[J].中国中医药信息杂志,2025,32(4):152-156,5.基金项目
国家自然科学基金(81973770) （81973770）
上海市进一步加快中医药事业发展三年行动计划(ZY(2018-2020)-FWTX-7005) （ZY(2018-2020）
